Atara biotherapeutics to participate at the evercore isi 5th annual healthconx conference

Thousand oaks, calif.--( business wire )--atara biotherapeutics, inc. (nasdaq: atra), a leader in t-cell immunotherapy, leveraging its novel allogeneic epstein-barr virus (ebv) t-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that pascal touchon, president and chief executive officer, will participate in a virtual fireside chat at the evercore isi 5th annual healthconx conference on wednesday, november 30, 2022, at 2:15 p.m. est.
ATRA Ratings Summary
ATRA Quant Ranking